JIPOAd
JIPOAd
PARP
ESID
  • Users Online: 149
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most cited articles *

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
ORIGINAL ARTICLES
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang
July-September 2018, 1(1):7-18
DOI:10.4103/JIPO.JIPO_12_18  
  8 1,873 312
EDITORIAL
Being realistic and optimistic in curing cancer
Aung Naing
October-December 2018, 1(2):53-55
DOI:10.4103/JIPO.JIPO_20_18  
  7 2,527 449
Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy
Joud Hajjar
July-September 2019, 2(3):53-54
DOI:10.4103/JIPO.JIPO_15_19  
  2 960 121
ORIGINAL ARTICLE
The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
Abdul Rahman Jazieh, Adda Bounedjar, Fouad Al Dayel, Shamayel Fahem, Arafat Tfayli, Kakil Rasul, Hassan Jaafar, Mohammad Jaloudi, Turki Al Fayea, Hatim Q Al Maghrabi, Hanaa Bamefleh, Khaled Al Kattan, Blaha Larbaoui, Taha Filali, Hamed Al Husaini, Yosra Ali, in collaboration with the Arab Collaborative Hematology Oncology Group (ACHOG)
January-March 2019, 2(1):4-7
DOI:10.4103/JIPO.JIPO_22_18  
  2 1,825 131
REVIEW ARTICLE
Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials
Haelee M Chin, David K Lai, Gerald S Falchook
January-March 2019, 2(1):10-16
DOI:10.4103/JIPO.JIPO_17_18  
  2 1,727 281
CASE REPORTS
Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy
Macartney E Welborn, Shelby L Kubicki, Anisha B Patel
October-December 2018, 1(2):82-84
DOI:10.4103/JIPO.JIPO_11_18  
  1 1,012 125
Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab
Amulya Balagani, Muhammad H Arain, Ajay Sheshadri
July-September 2018, 1(1):49-52
DOI:10.4103/JIPO.JIPO_8_18  
  1 1,142 118
ORIGINAL ARTICLES
Erlotinib in patients with advanced non-small cell lung cancer in Middle Eastern population
Abdul Rahman Jazieh, Turki M Fayea, Mervat Mahrous, Tarek Darwish, Essam Fawzi, Ashwaq A Alolayan, Nagham Sheblaq, Mohammed Alkaiyat, Yosra Ali
July-September 2018, 1(1):19-25
DOI:10.4103/JIPO.JIPO_2_18  
  1 2,074 164
REVIEW ARTICLES
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Abdulrazzak Zarifa, Mohammed Salih, Juan Lopez-Mattei, Hun Ju Lee, Cezar Iliescu, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Elie Mouhayar, Joseph Kim, Peter Kim
October-December 2018, 1(2):68-77
DOI:10.4103/JIPO.JIPO_15_18  
  1 2,082 280
Should we design clinical trials differently in the era of cancer immunotherapy?
Chia-Chi Lin
April-June 2019, 2(2):36-39
DOI:10.4103/JIPO.JIPO_5_19  
  1 1,283 168
Review: The impact of HIV infection on cancer treatment with immunotherapy
Bruno Palma Granwehr
July-September 2019, 2(3):85-92
DOI:10.4103/JIPO.JIPO_14_19  
  1 494 46
Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review
Ahmad Daher, Carlos Kamiya Matsuoka, Monica Elena Loghin, Marta Penas-Prado, Sudhakar Tummala
July-September 2019, 2(3):93-100
DOI:10.4103/JIPO.JIPO_3_19  
  1 926 71
* Source: CrossRef